Evidence map›Paper›PMID 37152882›Full record

ArticleActa endocrinologica (Bucharest, Romania : 2005)

A non-invasive method for estimating the severity of liver steatosis and the risk of fibrosis in non-obese type 2 diabetes patients with NAFLD.

B Mitrovic, Z Gluvic, A Klisic, M Obradovic, D Macut, R Tomasevic, E R Isenovic

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

B MitrovicZemun Clinical Hospital, Faculty of Medicine, University of Belgrade - Department of Endocrinology and Diabetes, Belgrade, Serbia.
Z GluvicZemun Clinical Hospital, Faculty of Medicine, University of Belgrade - Department of Endocrinology and Diabetes, Belgrade, Serbia.
A KlisicPrimary Health Care Center, University of Montenegro, Faculty of Medicine, Podgorica, Montenegro.
M ObradovicVINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade - Department of Radiobiology and Molecular Genetics.
D MacutUniversity of Belgrade Faculty of Medicine - Clinic of Endocrinology, Diabetes and Diseases of Metabolism.
R TomasevicZemun Clinical Hospital, Faculty of Medicine, University of Belgrade - Department of Gastroenterology and Hepatology Belgrade, Serbia.
E R IsenovicVINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade - Department of Radiobiology and Molecular Genetics.
Zemun Hospital · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Prognostic considerations include assessing the risk of liver fibrosis in people with non-alcoholic fatty liver disease (NAFLD). Objectives: This study evaluates the use of hematologic and metabolic parameters regarding liver steatosis and fibrosis scores (FLI and Fib-4) in non-obese type 2 diabetes mellitus (t2DM) patients with NAFLD. Methods: Subjects underwent abdominal ultrasound examinations, and FLI and Fib-4 scores were calculated to evaluate liver steatosis and the risk of liver fibrosis non-invasively: 61 non-obese NAFLD subjects with t2DM were included in the cohort study and were divided into 2 groups depending on the t2DM treatment regimen. Results: Fib-4 and WBC count demonstrated a significant inverse correlation (OR = 0.509, p = 0.007). WBC count had an R2 of 0.237, indicating that this marker could account for up to 23.7% of a variation in Fib-4. Fib-4 and FFA had positive correlation which did not achieve statistically significant prediction (OR=7.122, p=0.062). Additionally, a significant prediction of HbA1c (OR=1.536, p=0.016) and haemoglobin (OR=1.071, p=0.020) for FLI was revealed. Conclusion: HbA1c and other haematological and metabolic parameters, such as haemoglobin and WBC, may be another non-invasive tool for determining whether non-obese NAFLD patients with t2DM are at risk of developing liver steatosis and fibrosis.

Indexed as

Fib-4FLI scoreliver biopsyliver fibrosisNAFLDt2DM

Identifiers

PMID37152882
PMCPMC10162827
OpenAlexW4367725411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.